Search results
Could better asthma inhalers help patients, and the planet too?
NPR· 2 days agoThe Agency for Healthcare Research and Quality recommends that hospitals looking to shrink their...
Senator slams drugmaker for seeming to skirt pledge to cap inhaler cost
The Hill via AOL· 5 days agoDrug manufacturing giant GSK is subverting its pledge to lower the price of its brand-name inhaler...
Opinion | How the FTC Protects Patients in Healthcare
MedPage Today· 24 hours agoIn Part 1 of this exclusive video interview, MedPage Today editor-in-chief Jeremy Faust, MD, and Lina Khan, JD, chair of the Federal Trade Commission (FTC), discuss the agency's role in healthcare ...
The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences - April 2024 | JD...
JD Supra· 22 hours agoFollowing that policy statement, the FTC then challenged more than 100 patents held by ten different manufacturers of brand-name asthma inhalers, epinephrine autoinjectors ...
Sen. Hassan slams GlaxoSmithKline over cost of asthma inhalers
New Hampshire Union Leader· 6 days agoPharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a...
FTC disputes new slate of Orange Book patents for weight loss, diabetes, asthma, and COPD drugs | JD...
JD Supra· 22 hours agoOn April 30, 2024, the Federal Trade Commission (FTC) announced that it sent a new set of warning letters to ten pharmaceutical companies. The...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 7 days agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...
Better Health Care Newsletter - May 2024 | JD Supra
JD Supra· 22 hours agoFederal officials have capped the cost of insulin at $35 a month. For now, that gives relief only to patients 65 and older covered by Medicare. Big...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024
The FTC Strikes Again – Challenging the Listing of 300+ Patents in FDA’s Orange Book | JD Supra
JD Supra· 5 days agoThe warning letters stated that the identified patents were not necessarily an exhaustive list and stressed the companies’ burden to ensure patents in the Orange Book are ...
